Could You Have Seen The Run In Guardant Health Stock Coming?
Yahoo! Finance ·
Key points
- Shield received FDA approval in July 2024 and Medicare coverage, placing its progress on the record more than eight months before November 2025.
- In June 2025, the NCCN added Shield to its colorectal cancer screening guidelines, signaling broader clinical adoption despite Shield still being early in its commercial trajectory.
- Guardant’s revenue growth accelerated in 2025, with 2025 quarters showing 20.8% and 30.9% year-over-year gains, and a September 2025 quarter delivering 38.5% revenue growth while reducing the operating loss as a share of revenue from 54.6% to 37.3%.
- By September 2026, screening revenue reached $68 million in the quarter, representing roughly one-fifth of total quarterly revenue of $361 million, underscoring Shield’s outsize contribution.
- Shield volume jumped 246% in Q3 2026 to 83,000 tests, aided by UnitedHealthcare coverage that started in August and an estimated 100 million people set to be covered by early 2027.
- Management projects screening as a stand-alone business to reach cash-flow breakeven by the end of 2028, while the company as a whole targets breakeven by the end of 2027, despite ongoing operating losses relative to revenue.
- CMS claim-processing delays pushed free cash flow burn for 2026 up to a revised range of $205–$220 million, with payments expected to shift to the first half of 2027.
Summary
Guardant Health’s stock surged as Shield, its colorectal cancer screening test, emerged as the fastest-growing business after FDA approval and Medicare coverage, with management signaling progress toward profitability as the rest of the portfolio began contributing. By late 2025, Shield’s momentum was accompanied by accelerating overall revenue growth and a narrowing operating loss, while the company anticipated cash-flow breakeven for the screening unit by 2028 and company breakeven by 2027. The 2026 period reinforced Shield’s volume gains and payer expansion, even as total operating loss remained a focus. Looking ahead, management expects broader access (e.g., UnitedHealthcare coverage) and continued adoption to lift Shield and the standalone screening unit, with the broader business aiming for net profitability by 2027.
This summary was written with AI. The full story has every detail.